Queen's University at Kingston

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1841-10-16

Employees: 1K

Market Cap: -

Website: http://www.queensu.ca

Clinical Trials

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Phase 2

Conditions: Advanced Rare Tumours

Interventions: Drug: Durvalumab
Drug: Tremelimumab

First Posted Date: 2016-08-25

Last Posted Date: 2022-01-26

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 140

Registration Number: NCT02879162

Locations: 🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦
CancerCare Manitoba, Winnipeg, Manitoba, Canada
🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada

and more 10 locations

Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma

Phase 2

Active, not recruiting

Conditions: Pancreatic Adenocarcinoma

Interventions: Drug: Gemcitabine
Drug: Nab-paclitaxel
Drug: Durvalumab
Drug: Tremelimumab

First Posted Date: 2016-08-25

Last Posted Date: 2024-03-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 180

Registration Number: NCT02879318

Locations: 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada

and more 24 locations

Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Tremelimumab
Drug: Durvalumab
Other: Best Supportive Care

First Posted Date: 2016-08-17

Last Posted Date: 2023-12-08

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 180

Registration Number: NCT02870920

Locations: 🇨🇦
CHUQ-Pavillon Hotel-Dieu de Quebec, Quebec City, Quebec, Canada
🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦
Hopital de la Cite-de-la-Sante, Laval, Quebec, Canada

and more 22 locations

The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients

Phase 3

Completed

Conditions: Major Depressive Disorder
Depressive Symptoms
Depression

Interventions: Dietary Supplement: Probio'Stick

First Posted Date: 2016-07-20

Last Posted Date: 2019-06-14

Lead Sponsor: Queen's University

Target Recruit Count: 10

Registration Number: NCT02838043

Locations: 🇨🇦
Queen's University, Kingston, Ontario, Canada
🇨🇦
Providence Care - Mental Health Services, Kingston, Ontario, Canada

Duration of Anti-PD-1 Therapy in Metastatic Melanoma

Phase 3

Recruiting

Conditions: Unresectable/Metastatic Melanoma

Interventions: Drug: Continuous PD-1 inhibitor therapy
Drug: Intermittent PD-1 inhibitor therapy

First Posted Date: 2016-07-01

Last Posted Date: 2024-11-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 614

Registration Number: NCT02821013

Locations: 🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇦🇺
Mildura Base Public Hospital, Victoria, Mildura, Australia
🇦🇺
Coffs Habour Health Campus - NCCI, Coffs Harbour, New South Wales, Australia

and more 29 locations

The Effects of ECT and/or iTBS on Olfaction and Cognition in Patients With Depression

Completed

Conditions: Depression

Interventions: Device: Cognitive Function Imaging and Battery
Device: Sniffin Sticks
Other: Cognitive Batteries

First Posted Date: 2016-06-17

Last Posted Date: 2017-09-06

Lead Sponsor: Queen's University

Target Recruit Count: 30

Registration Number: NCT02804347

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Durvalumab
Drug: Tremelimumab

First Posted Date: 2016-06-02

Last Posted Date: 2024-12-17

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 52

Registration Number: NCT02788773

Locations: 🇨🇦
Allan Blair Cancer Centre, Regina, Saskatchewan, Canada
🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
Odette Cancer Centre, Toronto, Ontario, Canada

and more 8 locations

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Phase 2

Completed

Conditions: Mesothelioma

Interventions: Drug: Cisplatin
Drug: Pemetrexed
Drug: Pembrolizumab

First Posted Date: 2016-05-26

Last Posted Date: 2024-12-10

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 520

Registration Number: NCT02784171

Locations: 🇨🇦
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
🇫🇷
Institut Gustave-Roussy, Villejuif, FR, France
🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada

and more 53 locations

Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography Texture Analysis as a Predictive Biomarker

Phase 2

Terminated

Conditions: Metastatic Melanoma

Interventions: Drug: Pembrolizumab
Procedure: CT Scan

First Posted Date: 2016-04-15

Last Posted Date: 2023-08-25

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 9

Registration Number: NCT02740920

Locations: 🇨🇦
Kingston Health Sciences Centre, Kingston, Ontario, Canada
🇨🇦
London Regional Cancer Program, London, Ontario, Canada
🇨🇦
Odette Cancer Centre, Toronto, Ontario, Canada

and more 2 locations

Magnesium-Based Trigger Point Injections for Relief of Chronic Myofascial Pelvic Pain

Phase 3

Terminated

Conditions: Pelvic Pain

Interventions: Procedure: Magnesium-Based Injection Formulation
Procedure: Lidocaine-Only Injection Formulation
Drug: lidocaine
Drug: magnesium sulfate, bicarbonate, dextrose.

First Posted Date: 2016-04-05

Last Posted Date: 2023-03-31

Lead Sponsor: Queen's University

Target Recruit Count: 38

Registration Number: NCT02728037

Locations: 🇨🇦
Department of Obstetrics & Gynecology, Queen's Unviersity, Kingston, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy